한글목차

세계의 자동주사기 시장 규모는 2024년에 91억 5,000만 달러, 2030년에는 204억 3,000만 달러에 달하며, CAGR 14.28%로 성장할 것으로 예측됩니다.

자동주사기는 특히 만성질환이나 응급질환을 위한 약물을 쉽고 안전하게 자가 투여할 수 있도록 설계된 첨단 약물전달 기기입니다. 이러한 장비는 당뇨병, 자가면역질환, 아나필락시스와 같은 치료 영역에서 점점 더 많이 사용되고 있으며, 의사의 감독 없이도 편리함과 정확성을 제공합니다. 시장 성장은 전 세계에서 환자 중심 치료로의 전환과 재택 치료 옵션에 대한 선호도가 높아짐에 따라 성장세를 보이고 있습니다. 자동주사기는 인체공학적 디자인, 은폐된 바늘, 사전 계량된 용량과 같은 기능을 통해 치료 순응도를 향상시킵니다. 헬스케어 시스템이 가치 기반 치료를 중시하는 가운데, 자동주사기는 병원에 대한 의존도를 낮추고 임상 결과를 개선함으로써 지지를 받고 있습니다. 이 시장은 또한 생물제제와 사용하기 쉬운 전달 시스템의 조합에 초점을 맞춘 제약 혁신의 혜택을 누리고 있으며, 이는 자가 관리 치료의 추세를 지원하고 전 세계에서 자동주사기의 채택을 확대하고 있습니다.

시장 성장 촉진요인

만성질환 및 자가면역질환의 유병률 상승

주요 시장 이슈

높은 제조 및 개발 비용

주요 시장 동향

재택 및 자가 관리 치료 모델로의 전환

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 자동주사기 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 제품별(일회용 자동주사기, 재사용 가능 자동주사기(프리필드, 공))
  • 적응증별(류마티스 관절염, 다발성 경화증, 당뇨병, 아나필락시스, 기타)
  • 최종사용자별(홈케어 시설, 병원·진료소, 외래 수술 센터)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 자동주사기 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 자동주사기 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 자동주사기 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 자동주사기 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 자동주사기 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제13장 세계의 자동주사기 시장 : SWOT 분석

제14장 경쟁 구도

• Eli Lilly and Company
• SHL Medical AG
• AbbVie Inc
• Amgen Inc
• Owen Mumford Limited
• Ypsomed AG
• Teva Pharmaceutical Industries Ltd
• Biogen Inc.
• Viatris Inc
• Pfizer, Inc.
• Gerresheimer AG

제15장 전략적 제안

제16장 조사회사 소개·면책사항

영문목차

The Global Autoinjectors Market was valued at USD 9.15 Billion in 2024 and is projected to reach USD 20.43 Billion by 2030, growing at a CAGR of 14.28%. Autoinjectors are advanced drug delivery devices designed for easy and safe self-administration of medications, particularly for chronic and emergency conditions. These devices are increasingly used across therapeutic areas such as diabetes, autoimmune diseases, and anaphylaxis, offering convenience and accuracy without the need for medical supervision. The market's growth is propelled by the global shift toward patient-centric care and the rising preference for home-based treatment options. Autoinjectors improve treatment adherence through features such as ergonomic designs, concealed needles, and pre-measured doses. As healthcare systems emphasize value-based care, autoinjectors are gaining traction for reducing hospital dependency and enhancing clinical outcomes. The market also benefits from pharmaceutical innovation focused on pairing biologics with user-friendly delivery systems, supporting the trend of self-managed therapies and broadening the adoption of autoinjectors globally.

Key Market Drivers

Rising Prevalence of Chronic and Autoimmune Diseases

The growing incidence of chronic and autoimmune diseases is a primary factor driving demand for autoinjectors. Conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis are on the rise due to aging populations, lifestyle changes, and better diagnostics. For example, global diabetes prevalence is expected to increase from 537 million adults in 2024 to 643 million by 2030. These conditions often require long-term injectable therapies, making autoinjectors an effective solution for regular, accurate self-administration. By minimizing the complexity of injections and reducing the need for clinic visits, autoinjectors help patients maintain consistent treatment schedules, thereby improving health outcomes and adherence. Their ease of use also reduces the risk of dosage errors and needle anxiety. As healthcare systems aim to reduce costs and improve quality through better disease management, autoinjectors have become integral to chronic care strategies, further strengthening their market growth.

Key Market Challenges

High Manufacturing and Development Costs

Developing and producing autoinjectors involves significant investment due to their design complexity and regulatory requirements. These devices must meet stringent safety, compatibility, and performance standards, particularly when paired with biologics. Processes such as stability testing, risk analysis, and ensuring device-drug integration contribute to high R&D expenditures. Smaller pharmaceutical and biotech firms without in-house manufacturing capabilities often face financial barriers to market entry. Customization demands for different therapeutic areas and regions, as well as integration of digital features for monitoring, further increase development costs. These challenges are especially pronounced in developing regions where pricing pressure limits widespread adoption. The capital-intensive nature of the autoinjector segment remains a major constraint on scalability and profitability for emerging market players.

Key Market Trends

Shift Toward Home-Based and Self-Administered Treatment Models

A key trend transforming the autoinjectors market is the growing emphasis on home-based healthcare. Patients managing long-term conditions are increasingly seeking alternatives to frequent clinical visits. Autoinjectors support this shift by allowing individuals to self-administer medication safely and efficiently. Their user-friendly design, automatic needle retraction, and preset dosing mechanisms reduce the risk of misuse and improve adherence. This aligns with healthcare strategies aimed at lowering costs, reducing hospital load, and empowering patients. Pharmaceutical companies are responding by developing drugs compatible with autoinjector formats, thereby extending product lifecycles and enhancing market reach. As patient education and digital health adoption grow, autoinjectors are poised to become a standard component of modern chronic disease management and at-home care models.

Key Market Players

• Eli Lilly and Company
• SHL Medical AG
• AbbVie Inc
• Amgen Inc
• Owen Mumford Limited
• Ypsomed AG
• Teva Pharmaceutical Industries Ltd
• Biogen Inc.
• Viatris Inc
• Pfizer, Inc.
• Gerresheimer AG

Report Scope:

In this report, the Global Autoinjectors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Autoinjectors Market, By Product:

• Disposable Auto-injectors
• Reusable Auto-injectors

Autoinjectors Market, By Indication:

• Rheumatoid Arthritis
• Multiple Sclerosis
• Diabetes
• Anaphylaxis
• Other

Autoinjectors Market, By End User:

• Homecare Settings
• Hospitals & Clinics
• Ambulatory Surgical Centers

Autoinjectors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Autoinjectors Market.

Available Customizations:

Global Autoinjectors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Autoinjectors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Disposable auto-injectors, Reusable auto-injectors {Prefilled, Empty})
  • 5.2.2. By Indication (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, Other)
  • 5.2.3. By End User (Homecare Settings, Hospitals & Clinics, Ambulatory Surgical Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Autoinjectors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Autoinjectors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Autoinjectors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Autoinjectors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End User

7. Europe Autoinjectors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Autoinjectors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Autoinjectors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Autoinjectors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. France Autoinjectors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Autoinjectors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End User

8. Asia-Pacific Autoinjectors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Autoinjectors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Autoinjectors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Autoinjectors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Autoinjectors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Autoinjectors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End User

9. South America Autoinjectors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Autoinjectors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Autoinjectors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Autoinjectors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User

10. Middle East and Africa Autoinjectors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Autoinjectors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Autoinjectors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Autoinjectors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Autoinjectors Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Eli Lilly and Company
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. SHL Medical AG
• 14.3. AbbVie Inc
• 14.4. Amgen Inc
• 14.5. Owen Mumford Limited
• 14.6. Ypsomed AG
• 14.7. Teva Pharmaceutical Industries Ltd
• 14.8. Biogen Inc.
• 14.9. Viatris Inc
• 14.10.Pfizer, Inc.
• 14.11.Gerresheimer AG

15. Strategic Recommendations

16. About Us & Disclaimer